Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp® SPIROMAX® and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment

The main aim of the study is to investigate patient satisfaction in the treatment of asthma and COPD with the new device of DuoResp® Spiromax® and patient preference. Possible difficulties in the use of the device under real-life conditions in clinical practice are investigated.

The study detects the instruction expense in the use of the inhaler, reasons for the choice of the medication, or a switch in treatment of asthma or COPD.

Inclusion Criteria:

• male and female adult patients with clinical diagnosis of bronchial asthma or chronic obstructive pulmonary disease
• patients on regular medication with inhaled corticosteroids and long-acting beta-2-agonists in fixed-dose combination
• patients who recently changed medication to DuoResp® Spiromax or are about to do so
• capacitated person with present declaration of consent

Exclusion Criteria:

• diseases contraindicated in accordance with the summary of product characteristic
• patients who take part in interventional clinical trials parallel or during the last 4 weeks
• patient shows conditions or diseases that might disturb the monitoring according to the physician
• patients with substance misuse in their case history (drugs, alcohol) or with other factors (e.g. serious psychiatric conditions) that limit their ability to participate in the study
• insufficient German language knowledge to understand the patient education and to complete the questionnaires in a correct manner
• patients involved in the planning and construction of the study (Teva staff and employees of the centres)
• patient is incapable of giving consent